Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia-Reference-Cited by-同舟云学术

Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia

Published:2014-02-11 Issue:7 Volume:29 Page:935-939
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Boesch Sylvia¹,Nachbauer Wolfgang¹,Mariotti Caterina²,Sacca Francesco³,Filla Alessandro³,Klockgether Thomas⁴⁵,Klopstock Thomas⁶,Schöls Ludger⁷⁵,Jacobi Heike⁴,Büchner Boriana⁶,vom Hagen Jennifer Müller⁷,Nanetti Lorenzo²,Manicom Karen⁸

Affiliation:

1. Department of Neurology; Medical University Innsbruck; Innsbruck Austria

2. Unit of Genetics of Neurodegenerative and Metabolic Diseases; Fondazione IRCCS Istituto Neurologico “Carlo Besta,”; Milan Italy

3. Department of Neurological Sciences; Federico II University; Naples Italy

4. Department of Neurology; University Hospital of Bonn; Bonn Germany

5. German Center of Neurodegenerative Diseases (DZNE); Bonn Germany

6. Department of Neurology; Friedrich-Baur-Institute, University Hospital of Ludwig-Maximilians-University; Munich Germany

7. Department of Neurology and Hertie-Institute for Clinical Brain Research; University of Tübingen; Tübingen Germany

8. Department of ICR Neurology; H. Lundbeck; Copenhagen Denmark

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference37 articles.

1. Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene;Epplen;Hum Genet,1997

2. Friedreich's ataxia: clinical aspects and pathogenesis;Pandolfo;Semin Neurol,1999

3. Molecular basis of Friedreich ataxia;Pandolfo;Mov Disord,2001

4. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features;Harding;Brain,1981

5. Diagnosis and treatment of Friedreich ataxia: a European perspective;Schulz;Nat Rev Neurol,2009

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment and Management of Autosomal Recessive Cerebellar Ataxias: Current Advances and Future Perspectives;CNS & Neurological Disorders - Drug Targets;2023-06

2. Consensus Recommendations for Clinical Outcome Assessments and Registry Development in Ataxias: Ataxia Global Initiative (AGI) Working Group Expert Guidance;The Cerebellum;2023-04-05

3. Friedreich ataxia: clinical features and new developments;Neurodegenerative Disease Management;2022-10

4. Drug Repositioning in Friedreich Ataxia;Frontiers in Neuroscience;2022-02-09

5. Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review;Therapeutic Advances in Rare Disease;2022-01